This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Spyros Papapetropoulos

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3yrs

Recente managementupdates

Recent updates

CEO

Spyros Papapetropoulos (50 yo)

less than a year

Tenure

Dr. Spyridon Papapetropoulos, M. D., Ph. D., also known as Spyros, serves as Director, President & Chief Executive Officer at Bionomics Limited from January 05, 2023. He serves as Member of Scientific Advi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Adrian Hinton	Financial Controller	less than a year	AU$323.78k	0.0048% € 305.4
Spyridon Papapetropoulos	CEO, President & Director	less than a year	geen gegevens	geen gegevens
Timothy Cunningham	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Paul Rolan	Consultant Chief Medical Officer of Clinical Neuroscience	no data	AU$102.00k	geen gegevens
Julie Kerner	Senior Vice President of Business Operations	less than a year	geen gegevens	geen gegevens
Atul Mahableshwarkar	Acting Chief Medical Officer	less than a year	geen gegevens	geen gegevens
Suzanne Irwin	Company Secretary	2.4yrs	geen gegevens	geen gegevens

0.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van B1N wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Spyridon Papapetropoulos	CEO, President & Director	less than a year	geen gegevens	geen gegevens
Errol B. De Souza	Non-Executive Director	15.6yrs	AU$4.03m	0.025% € 1.6k
David Wilson	Independent Non-Executive Director	7.3yrs	AU$87.00k	0.017% € 1.1k
Alan Fisher	Independent Non-Executive Chair of the Board	7yrs	AU$87.00k	0.0068% € 436.1
Jane Ryan	Independent Non-Executive Director	2.9yrs	AU$93.15k	0% € 0
Srinivas Rao	Member of Clinical Advisory Board	1.9yrs	AU$57.75k	geen gegevens
Murray Stein	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Steven Williams	Scientific Advisor	no data	geen gegevens	geen gegevens
Allan Young	Scientific Advisor	no data	geen gegevens	geen gegevens
Marina Picciotto	Scientific Advisor	no data	geen gegevens	geen gegevens
Peter Miles Davies	Independent Non-Executive Director	2.2yrs	AU$77.00k	0.018% € 1.2k
Aaron N. Weaver	Independent Non-Executive Nominee Director	3.2yrs	AU$77.00k	geen gegevens

3.0yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van B1N wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

This company listing is no longer active

Bionomics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

High number of new directors

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Revenue beats expectations

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

New 90-day high: €0.27

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - €0.0082 loss per share

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd